Sex dimorphism in mTOR-longevity responses is pervasive and sometimes direction-flipping
Studies point in different directions · confidence 80% · Atlas ID H6
The gap
Male and female animals often respond differently to these drugs — sometimes just by how much, but sometimes the effect flips direction entirely. Rapamycin tends to help females somewhat more; a different drug, acarbose, helps males more. Females also build up higher drug levels in their blood after the same dose, which may explain part of it.
Technical framing: Emerged directly from the full-text effect sizes: S6K1-KO +19% median lifespan in FEMALES / no effect in males (SEL2009); rapamycin favors females (MIL2014 all doses in F vs top-2 in M; HAR2009 +38% F vs +28% M; FOK2014 +16% F vs +11% M; WUX2013 +22% F/+19% M); yet acarbose favors MALES (+22% vs +5%, HAR2014). Sex changes not just the magnitude but sometimes the DIRECTION of the response. BIT2016 QUALIFIED (2026-08-30): its male-benefit / female-harm result holds only for the high-dose 8 mg/kg/day injection arm. In the same paper's 126 ppm dietary arm, post-treatment survival rose significantly in both sexes and a Cox model found no evidence that sex modified the treatment effect (p=0.904). BIT2016 therefore supports DOSE-dependent dimorphism, not intrinsic dimorphism, and is as much a boundary case for this hypothesis as evidence for it. The thesis stands on SEL2009, MIL2014, HAR2009, FOK2014, WUX2013 and HAR2014.
The hypothesis
Educated guess: some of the sex difference is simply because females end up with more drug in their blood after the same dose — matching the dose to blood levels instead of body weight might close that gap for rapamycin, though probably not for acarbose, where the male/female difference looks more like a real biological difference in how the drug acts.
Technical framing: Sex-specific pharmacokinetics (females reach higher rapamycin blood levels, MIL2014) plus pharmacodynamic differences drive the dimorphism; matching blood exposure across sexes will narrow the gap for rapamycin, but not for interventions with the opposite skew (acarbose), which must be target-driven.
How it could be tested
Sex-stratified, dose-matched study: titrate rapamycin to equal blood levels in males and females; measure lifespan/healthspan + mTORC1 vs mTORC2 signaling, separating PK (exposure) from PD (tissue response). Repeat for acarbose to test whether its male-skew is exposure- or target-driven.